AURORA, Colo. – V. Michael Holers,
MD, professor of medicine at the University of Colorado School of Medicine,
leads one of the 11 research groups awarded grants this week by the National
Institutes of Health (NIH) to establish the Accelerating Medicine Partnership
in Rheumatoid Arthritis and Lupus Network.
total of $6 million of first-year funding was awarded by the NIH to create the
network, which is a public-private partnership developed by the NIH earlier
this year to transform the current model for identifying and validating
the most promising biological targets for the development of new drugs and
Holers laboratory and research group on the Anschutz Medical Campus focuses on
the evolution of autoimmunity in rheumatoid arthritis (RA), the early
pathogenesis of this disease and the development of prevention strategies and
and lupus are relatively common, severe autoimmune diseases. These disorders
share similar flaws in immune function and regulation, leading to inflammation
that damages tissues. RA and lupus can last a lifetime, cause severe
disability, greatly affect quality of life, and are associated with increased
risk of early death.
five years, the AMP RA/Lupus Network will analyze the interplay among
biological pathways, including at the single cell level, in tissues of patients
with RA and lupus. The goal is to integrate data from multiple genome-wide
analytic approaches to generate a comprehensive understanding of the mechanisms
of tissue damage in RA and lupus.
NIH announcement of the grants is available at http://www.nih.gov/news/health/sep2014/niams-24.htm.